” DT56a was effective against symptomatic vulvo-vaginal atrophy (vaginal dryness)…”

A Prospective Study of DT56a (Femarelle®) for the Treatment of Postmenopausal
Vaginal Atrophy

Published in: Journal of Endocrinological Investigation 2013;36(7):521-6.

Efficacy and safety of DT56a compared to hormone therapy in Greek post-menopausal women.

Labos G, Trakakis E, Pliatsika P, Augoulea A, Vaggopoulos V, Basios G, Simeonidis G, Creatsa M, Alexandrou A, Iliodromiti Z, Kassanos D, Lambrinoudaki I.

BACKGROUND:

Hormone therapy (HT) is the treatment of choice for the alleviation of menopausal symptoms; concerns, however, about its concomitant long-term health risks have limited its use. DT56a is a unique enzymatic isolate of soybeans. The purpose of our study was to evaluate the efficacy and safety of DT56a, compared to HT, in symptomatic post-menopausal women.

CONCLUSIONS:

DT56a decreased menopausal symptoms significantly and in the same degree as HT

For full abstract>